Please Wait
Applying Filters...
menu
    • menu
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Omecamtiv Mecarbil

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Cytokinetics Starts Comet-HF Ph 3 Trial for Heart Failure Treatment
    Cytokinetics Starts Comet-HF Ph 3 Trial for Heart Failure Treatment

    03 Dec 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/12/03/2990480/35409/en/Cytokinetics-Announces-Start-of-COMET-HF-a-Confirmatory-Phase-3-Clinical-Trial-of-Omecamtiv-Mecarbil-in-Patients-with-Symptomatic-Heart-Failure-with-Severely-Reduced-Ejection-Fract.html

    GLOBENEWSWIRE
    03 Dec 2024
    Share Share
    U.S. FDA declines to approve Cytokinetics' heart drug
    U.S. FDA declines to approve Cytokinetics' heart drug

    01 Mar 2023

    // REUTERS

    https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-declines-approve-cytokinetics-heart-drug-2023-02-28/

    REUTERS
    01 Mar 2023
    Share Share
    Cytokinetics' heart drug fails to secure FDA panel's support
    Cytokinetics' heart drug fails to secure FDA panel's support

    14 Dec 2022

    // Pratik Jain REUTERS

    https://www.reuters.com/business/healthcare-pharmaceuticals/cytokinetics-heart-drug-fails-secure-fda-panels-support-2022-12-13/

    Pratik Jain REUTERS
    14 Dec 2022
    Share Share
    FDA staff reviewers flag safety concerns over Cytokinetics' heart drug
    FDA staff reviewers flag safety concerns over Cytokinetics' heart drug

    10 Dec 2022

    // REUTERS

    https://www.reuters.com/business/healthcare-pharmaceuticals/fda-staff-reviewers-flag-safety-concerns-over-cytokinetics-heart-drug-2022-12-09/

    REUTERS
    10 Dec 2022
    Share Share
    Cytokinetics Announces Availability of Documents for FDA Meeting on Omecamtiv Mecarbil
    Cytokinetics Announces Availability of Documents for FDA Meeting on Omecamtiv Mecarbil

    09 Dec 2022

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2022/12/09/2571098/35409/en/Cytokinetics-Announces-Availability-of-Briefing-Documents-for-FDA-Advisory-Committee-Meeting-on-Omecamtiv-Mecarbil.html

    GLOBENEWSWIRE
    09 Dec 2022
    Share Share
    Cytokinetics Announces Date for FDA Meeting to Review NDA for Omecamtiv Mecarbil
    Cytokinetics Announces Date for FDA Meeting to Review NDA for Omecamtiv Mecarbil

    24 Jun 2022

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2022/06/24/2468701/35409/en/Cytokinetics-Announces-Date-for-FDA-Advisory-Committee-Meeting-to-Review-New-Drug-Application-for-Omecamtiv-Mecarbil.html

    GLOBENEWSWIRE
    24 Jun 2022
    Share Share